ARDX · Ardelyx, Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-06 |
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 million Strong financial position with $281.8 million in cash, cash equivalents |
| 2026-07-23 |
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet |
| 2026-05-19 |
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its |
| 2026-05-07 |
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis |
| 2026-04-30 |
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million Strong financial position with $238.1 million in cash, cash equivalents and investments as of March |
| 2026-04-27 |
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative |
| 2026-04-23 |
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient |
| 2026-04-20 |
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. |
| 2026-04-16 |
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet |
| 2026-04-01 |
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical |
| 2026-03-12 |
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Award recognizes leading chronic kidney disease advocates WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, |
| 2026-03-09 |
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-06 | Ardelyx Q2 2026 Earnings | Earnings call |
| 2026-06-03 | Jefferies Global Healthcare Conference in New York | Conference |
| 2026-04-30 | Ardelyx Q1 2026 Earnings | Earnings call |
| 2026-03-10 | Leerink Partners 2026 Global Healthcare Conference in Miami | Conference |
| 2026-02-19 | Ardelyx Q4 2025 Earnings | Earnings call |
| 2025-11-19 | Jefferies Global Healthcare Conference in London | Conference |
| 2025-11-10 | Wedbush Rewind American Society of Nephrology 2025 Investor Conference | Conference |
| 2025-10-30 | Ardelyx Q3 2025 Earnings | Earnings call |
| 2025-09-09 | H.C. Wainwright 27th Annual Global Investment Conference | Conference |
| 2025-09-08 | Morgan Stanley 23rd Annual Global Healthcare Conference | Conference |
| 2025-09-04 | Cantor Global Healthcare Conference | Conference |
Source: https://ir.ardelyx.com/